Unique ID issued by UMIN | UMIN000008046 |
---|---|
Receipt number | R000009476 |
Scientific Title | Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors. |
Date of disclosure of the study information | 2012/05/28 |
Last modified on | 2013/05/31 11:14:26 |
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
Japan |
Malignant tumor
Medicine in general | Gastroenterology | Hepato-biliary-pancreatic medicine |
Cardiology | Pneumology | Endocrinology and Metabolism |
Hematology and clinical oncology | Nephrology | Surgery in general |
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Vascular surgery |
Chest surgery | Endocrine surgery | Breast surgery |
Obstetrics and Gynecology | Dermatology | Oto-rhino-laryngology |
Urology | Oral surgery | Neurosurgery |
Malignancy
NO
To examine the stability of NK cell culture technology, and investigate efficacy of NK cell therapy for malignant tumors.
Safety,Efficacy
Pragmatic
Not applicable
To examine the stability of NK cell culture technology and explore improvement factors of NK cell cultivation.
Safety
Immunological responses
Efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
NK cells are injected on day0, day14, day28, day42, day56, day70.
20 | years-old | <= |
Not applicable |
Male and Female
(1) Patients with histologically confirmed malignant tumors.
(2) Performance Status is 0-2.
(3) No serious abnormality in bone marrow, liver, and renal functions.
(4) Informed consent has been obtained.
Patients who have:
(1) Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them;
(2) Serious drug allergy;
(3) Positive for HIV or HTLV-1;
(4) Active autoimmune disease;
(5) Continuous systemic administration of steroids;
(6) Other cancers;
(7) Active infections;
(8) Pregnant or lactating;
(9) T cell, NK cell lymphoma and leukemia;
(10) Serious cardiac disease;
(11) Any reason why, in the opinion of the investigator, the patient should not participate.
20
1st name | |
Middle name | |
Last name | Takashi Kamigaki |
Seta Clinic Group
Clinical reserch center
8F Kokoro to Karada no genki pulaza Bld. 3-6-5 Iidabashi, Chiyoda-ku Tokyo, 102-0072 JAPAN
03-5215-0086
1st name | |
Middle name | |
Last name | Hiroshi Ibe |
Seta Clinic Group
Clinical research center
8F Kokoro to Karada no genki pulaza Bld. 3-6-5 Iidabashi, Chiyoda-ku Tokyo, 102-0072 JAPAN
03-5215-0086
scrc@j-immunother.com
Seta Clinic Group
Medinet Co.,Ltd.
Profit organization
NO
瀬田クリニックグループ
2012 | Year | 05 | Month | 28 | Day |
Unpublished
Completed
2012 | Year | 05 | Month | 11 | Day |
2012 | Year | 05 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2012 | Year | 05 | Month | 28 | Day |
2013 | Year | 05 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009476
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |